Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $7,765 | 517 | 98.7% |
| Education | $62.17 | 5 | 0.8% |
| Consulting Fee | $22.48 | 1 | 0.3% |
| Debt forgiveness | $20.33 | 1 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $2,448 | 166 | $0 (2024) |
| PFIZER INC. | $944.22 | 49 | $0 (2024) |
| Merck Sharp & Dohme LLC | $636.14 | 38 | $0 (2024) |
| Allergan, Inc. | $576.65 | 89 | $0 (2020) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $498.31 | 29 | $0 (2024) |
| Celgene Corporation | $330.74 | 18 | $0 (2024) |
| IRONWOOD PHARMACEUTICALS, INC | $300.48 | 17 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $219.11 | 13 | $0 (2022) |
| Gilead Sciences, Inc. | $195.16 | 12 | $0 (2024) |
| Synergy Pharmaceuticals Inc | $169.79 | 16 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,229 | 68 | ABBVIE INC. ($273.34) |
| 2023 | $1,217 | 64 | Celgene Corporation ($240.29) |
| 2022 | $953.55 | 51 | ABBVIE INC. ($262.91) |
| 2021 | $991.03 | 67 | AbbVie Inc. ($405.70) |
| 2020 | $828.70 | 56 | AbbVie Inc. ($359.23) |
| 2019 | $779.27 | 72 | AbbVie, Inc. ($309.85) |
| 2018 | $1,092 | 89 | AbbVie, Inc. ($369.50) |
| 2017 | $780.11 | 57 | AbbVie, Inc. ($238.19) |
All Payment Transactions
524 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/14/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $17.21 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/09/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $22.80 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/25/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $23.39 | General |
| Category: IMMUNOLOGY | ||||||
| 11/18/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $21.50 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/11/2024 | Lucid Diagnostics Inc. | — | Food and Beverage | In-kind items and services | $15.15 | General |
| 11/08/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug) | Food and Beverage | In-kind items and services | $22.53 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/04/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $18.28 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/28/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $21.05 | General |
| Category: IMMUNOLOGY | ||||||
| 10/22/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $108.59 | General |
| Category: Immunology | ||||||
| 10/21/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $16.23 | General |
| Category: ENDOCRINOLOGY | ||||||
| 10/18/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $20.51 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 10/15/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $5.44 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/07/2024 | IRONWOOD PHARMACEUTICALS, INC | Linzess (Drug) | Food and Beverage | Cash or cash equivalent | $20.40 | General |
| Category: GI | ||||||
| 10/07/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $17.53 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/30/2024 | ABBVIE INC. | CREON (Drug), VIBERZI, LINZESS | Food and Beverage | In-kind items and services | $16.26 | General |
| Category: ENDOCRINOLOGY | ||||||
| 09/23/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $20.88 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 09/16/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $14.12 | General |
| 09/10/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $5.01 | General |
| Category: ENDOCRINOLOGY | ||||||
| 09/09/2024 | Lucid Diagnostics Inc. | — | Food and Beverage | In-kind items and services | $13.96 | General |
| 09/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $18.52 | General |
| Category: Neuroscience | ||||||
| 09/04/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $3.25 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/02/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $17.51 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/28/2024 | EVOKE PHARMA, INC. | GIMOTI (Drug) | Food and Beverage | In-kind items and services | $19.40 | General |
| Category: Gastroenterology | ||||||
| 08/23/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug) | Food and Beverage | In-kind items and services | $30.32 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/19/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $18.94 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 1,576 | 2,862 | $702,596 | $248,351 |
| 2022 | 15 | 1,857 | 3,378 | $770,497 | $287,059 |
| 2021 | 15 | 1,613 | 2,813 | $641,380 | $248,793 |
| 2020 | 14 | 1,796 | 3,617 | $795,675 | $298,260 |
All Medicare Procedures & Services
59 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 413 | 820 | $147,693 | $75,747 | 51.3% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2023 | 176 | 655 | $114,590 | $35,507 | 31.0% |
| 88312 | Special stained specimen slides to identify organisms including interpretation and report | Office | 2023 | 142 | 311 | $63,052 | $26,373 | 41.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 199 | 199 | $44,249 | $24,035 | 54.3% |
| 88313 | Special stained specimen slides to examine tissue including interpretation and report | Office | 2023 | 138 | 343 | $51,591 | $21,126 | 40.9% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 222 | 244 | $114,110 | $18,118 | 15.9% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 76 | 77 | $52,059 | $15,739 | 30.2% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 37 | 37 | $21,749 | $6,673 | 30.7% |
| 91110 | Imaging of digestive tract done from the inside of the digestive tract | Office | 2023 | 12 | 12 | $14,400 | $6,450 | 44.8% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 48 | 49 | $28,480 | $4,874 | 17.1% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 28 | 29 | $14,500 | $4,059 | 28.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 25 | 26 | $7,254 | $3,485 | 48.0% |
| 43248 | Insertion of guide wire with dilation of esophagus using a flexible endoscope | Facility | 2023 | 30 | 30 | $14,070 | $3,156 | 22.4% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 13 | 13 | $7,999 | $2,246 | 28.1% |
| 45331 | Biopsy of lower large bowel using a flexible endoscope | Facility | 2023 | 17 | 17 | $6,800 | $764.91 | 11.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 427 | 757 | $124,905 | $70,586 | 56.5% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2022 | 231 | 888 | $155,400 | $48,636 | 31.3% |
| 88312 | Special stained specimen slides to identify organisms including interpretation and report | Office | 2022 | 184 | 400 | $80,000 | $34,362 | 43.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 255 | 255 | $51,765 | $29,696 | 57.4% |
| 88313 | Special stained specimen slides to examine tissue including interpretation and report | Office | 2022 | 184 | 471 | $70,650 | $29,010 | 41.1% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 257 | 282 | $121,542 | $21,169 | 17.4% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 72 | 73 | $41,975 | $14,926 | 35.6% |
| 91110 | Imaging of digestive tract done from the inside of the digestive tract | Office | 2022 | 13 | 13 | $15,600 | $7,830 | 50.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 47 | 49 | $13,671 | $7,720 | 56.5% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 29 | 29 | $16,617 | $5,321 | 32.0% |
About Thimmiah Kumar, M. D
Thimmiah Kumar, M. D is a Specialist healthcare provider based in Ocala, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/06/2005. The National Provider Identifier (NPI) number assigned to this provider is 1629062617.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Thimmiah Kumar, M. D has received a total of $7,870 in payments from pharmaceutical and medical device companies, with $1,229 received in 2024. These payments were reported across 524 transactions from 35 companies. The most common payment nature is "Food and Beverage" ($7,765).
As a Medicare-enrolled provider, Kumar has provided services to 6,842 Medicare beneficiaries, totaling 12,670 services with total Medicare billing of $1.1M. Data is available for 4 years (2020–2023), covering 59 distinct procedure/service records.
Practice Information
- Specialty Specialist
- Location Ocala, FL
- Active Since 09/06/2005
- Last Updated 04/04/2014
- Taxonomy Code 174400000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1629062617
Products in Payments
- XELJANZ (Drug) $881.15
- LINZESS (Drug) $839.60
- DIFICID (Drug) $528.90
- MAVYRET (Drug) $392.45
- Mavyret (Drug) $370.40
- CREON (Drug) $309.01
- ZEPOSIA (Drug) $304.34
- XIFAXAN (Drug) $289.59
- VIBERZI (Drug) $284.56
- Humira (Biological) $272.26
- Linzess (Drug) $235.21
- HUMIRA (Biological) $214.81
- DUPIXENT (Biological) $200.64
- RELISTOR (Drug) $173.31
- Trulance (Drug) $169.79
- Creon (Drug) $122.17
- IBSRELA (Drug) $121.02
- OCALIVA (Drug) $120.47
- Viekira (Drug) $117.10
- STELARA (Biological) $113.33
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Ocala
Paul Jo, Md, MD
Specialist — Payments: $38,061
Dr. John Gresh, Md, MD
Specialist — Payments: $7,227
Vishnu Reddy, M. D, M. D
Specialist — Payments: $4,789
Amruth Bapatla, Md, MD
Specialist — Payments: $3,858
Dr. James Paraiso, Do, DO
Specialist — Payments: $3,042
Dr. Samantha Johnson, Dnp, DNP
Specialist — Payments: $2,174